China-based biopharmaceutical company Canbridge Life Sciences secured $10m yesterday in a series A round that included TF Capital, a venture fund set up by China-based contract research organisation Tigermed.

The round also included venture capital firm Qiming Venture Partners, which focuses on early-stage companies in the media, internet, IT, consumer, retail, healthcare and cleantech sectors.

Canbridge, launched in 2012, signs partnership agreements with biopharmaceutical firms in the west to bring clinical-stage drugs and devices to China and North Asia, and…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?